InvestorsHub Logo
Followers 18
Posts 932
Boards Moderated 0
Alias Born 04/26/2016

Re: moosedogger post# 6850

Wednesday, 04/11/2018 10:55:57 AM

Wednesday, April 11, 2018 10:55:57 AM

Post# of 17448
Yeah, it was detailed out in their 40-K annual report. Essentially, generics were coming out that deterred them from putting the resources into the trial. Financially it wasn't as attractive as an indication anymore. They actually even had a SPA for the trial. People forget VOC did well in the transplant studies. They decided to put their $ towards LN and developed Aurinia. It seems like they thought LN would be the best risk/reward option to get VOC to market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News